Efficacy and Safety of Broncho Muco Cleaner Balloon Dilation Therapy
NCT05868941 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2025-07-03
Summary
In COPD patients with chronic bronchitis, it is aimed to determine whether the broncho muco cleaner balloon dilation method can provide clinical and functional benefit by causing destruction in hyperplasic goblet cells in the bronchial system. Although 2 studies have been published on this subject before, one of them is a retrospective design and the other is a pilot study consisting of only 10 patients . Therefore, it is clear that it should be supported by a controlled prospective study with more patients.
Within the scope of the research, broncho muco cleaner balloon dilatation treatment will be performed with fiberoptic bronchoscope under general anesthesia in chronic bronchitis-predominant COPD cases, and the effectiveness and reliability of the procedure will be evaluated.
Conditions
Interventions
- DEVICE
-
Broncho Muco Cleaner
The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract. In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally.
Sponsors & Collaborators
-
Klinar CRO
collaborator OTHER -
Clinodevice
lead INDUSTRY
Principal Investigators
-
Erdogan Cetinkaya · stanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 40 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-02-02
- Primary Completion
- 2025-03-17
- Completion
- 2025-06-23
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Autologous Transplantation of Bronchial Basal Cells for Treatment of Bronchiectasis
NCT03655808 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
NCT01727141 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
NCT01005901 ·Status: COMPLETED ·Phase: PHASE3
-
Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR)
NCT04140214 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
NCT06958861 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00268216 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01475292 ·Status: COMPLETED ·Phase: PHASE2
-
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00929110 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis
NCT01769898 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD
NCT04675463 ·Status: UNKNOWN ·Phase: NA
-
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
NCT01313637 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating Bronchodilator Response in Patients With Bronchiectasis
NCT05932316 ·Status: UNKNOWN ·Phase: NA
-
Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Qingkepingchuan Granules Clinical Observation of Phlegm-Heat and Lung Depletion
NCT06143358 ·Status: COMPLETED ·Phase: NA
-
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
NCT02516592 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
NCT00358436 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Oral Doxofylline and Procaterol on Chronic Obstructive Pulmonary Disease
NCT06346691 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00856193 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT04268823 ·Status: TERMINATED ·Phase: PHASE2
-
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
NCT05987371 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD
NCT03745261 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety Study of QVA149 in COPD Patients
NCT02487446 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Long-term Safety of QVA149
NCT01120717 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
NCT02700919 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Budesonide-Formoterol in Bronchiectasis
NCT00728715 ·Status: COMPLETED ·Phase: NA